Long-term outcomes of anti-CD19 CAR T cell therapy in refractory myasthenia gravis: A case series.

Hegelmaier T, Motte J, Walther D, Feist E, Duscha A, Desel C, Pappa V, Böttcher M, Voigt M, Sgodzai M, Al-Dubai M, Schroers R, Borie D, Schett G, Mougiakakos D, Gold R, Haghikia A

Open source

DOI
10.1016/j.xcrm.2026.103000
Published
2026 Sep 15
Container
Cell reports. Medicine
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.xcrm.2026.103000,
  title = {Long-term outcomes of anti-CD19 CAR T cell therapy in refractory myasthenia gravis: A case series.},
  author = {Hegelmaier T and Motte J and Walther D and Feist E and Duscha A and Desel C and Pappa V and Böttcher M and Voigt M and Sgodzai M and Al-Dubai M and Schroers R and Borie D and Schett G and Mougiakakos D and Gold R and Haghikia A},
  year = {2026},
  journal = {Cell reports. Medicine},
  doi = {10.1016/j.xcrm.2026.103000},
  url = {https://doi.org/10.1016/j.xcrm.2026.103000}
}

RIS

TY  - JOUR
TI  - Long-term outcomes of anti-CD19 CAR T cell therapy in refractory myasthenia gravis: A case series.
AU  - Hegelmaier T
AU  - Motte J
AU  - Walther D
AU  - Feist E
AU  - Duscha A
AU  - Desel C
AU  - Pappa V
AU  - Böttcher M
AU  - Voigt M
AU  - Sgodzai M
AU  - Al-Dubai M
AU  - Schroers R
AU  - Borie D
AU  - Schett G
AU  - Mougiakakos D
AU  - Gold R
AU  - Haghikia A
PY  - 2026
JO  - Cell reports. Medicine
DO  - 10.1016/j.xcrm.2026.103000
UR  - https://doi.org/10.1016/j.xcrm.2026.103000
ER  - 

APA

T, H., J, M., D, W., E, F., A, D., C, D., V, P., M, B., M, V., M, S., M, A., R, S., D, B., G, S., D, M., R, G., & A, H. (2026). Long-term outcomes of anti-CD19 CAR T cell therapy in refractory myasthenia gravis: A case series.. Cell reports. Medicine. https://doi.org/10.1016/j.xcrm.2026.103000

Source records